gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 02 Oct 2014.

Leucine-rich repeat kinase 2

LRRK2, leucine-rich repeat kinase 2, PARK8
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: AGE, E3 ubiquitin ligase, PINK1, CAN, DJ-1
Papers using LRRK2 antibodies
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Supplier
Lightowlers Bob, In PLoS ONE, 2009
... For LRRK2, rabbit monoclonal MJFF2 (Epitomics – see ...
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
Supplier
Kahle Philipp J., In PLoS ONE, 2009
... ReagentsAll cell culture media and supplements, BacMam LRRK2-GFP reagents, PrestoBlue™ cell viability assay reagent, Western blotting reagents and human neural stem cells were obtained from Life Technologies (Carlsbad, CA) ...
Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors
Supplier
Xia Xu-Gang et al., In International Journal of Biological Sciences, 2008
... LRRK2 and tTA transgenic rats were produced by ...
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
Supplier
Feany Mel B., In PLoS ONE, 2007
... Full length WT-LRRK2 pCMV6-XL5 was purchased from Origene (NM_198578.2) ...
Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
Supplier
Hart Anne C., In PLoS ONE, 2006
... driven WT or mutant LRRK2 constructs, were injected with the co-injection marker, promoter of nmr-1 driven YFP2 [55], into transgenic wild type nematode lines ...
more suppliers
Papers on LRRK2
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
New
Escudier et al., Villejuif, France. In Clin Cancer Res, Aug 2014
We validated LRRK2 cokinase as highly correlated to MET expression.
Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
New
Gillardon et al., Biberach an der Riß, Germany. In Glia, Jul 2014
Increasing evidence suggests that Parkinson's disease (PD)-linked Leucine-rich repeat kinase 2 (LRRK2) has a role in peripheral and brain-resident immune cells.
Genetic mutations in early-onset Parkinson's disease Mexican patients: molecular testing implications.
New
López-López et al., Chiconcuac, Mexico. In Am J Med Genet B Neuropsychiatr Genet, Apr 2014
All individuals had been previously screened for the three most common LRRK2 mutations.
Association studies of sporadic Parkinson's disease in the genomic era.
New
Ross et al., Jacksonville, United States. In Curr Genomics, Feb 2014
The first loci to be nominated were previously associated to familial PD (SNCA, MAPT, LRRK2) and these have been extensively replicated.
The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Review
New
Motherwell et al., United States. In Gene, Jan 2014
The genetic mutations of Parkinson's related proteins such as PINK1 and LRRK2 contribute to mitochondrial dysfunction which precedes ROS formation.
LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease.
Review
New
Lee et al., Seoul, South Korea. In Exp Neurobiol, Dec 2013
LRRK2 is another protein linked to the pathogenesis of PD, and its presence in Lewy bodies has attracted much attention as to whether LRRK2 and α-synuclein interplay during the pathogenesis of PD.
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?
New
Greggio et al., Padova, Italy. In J Neuroinflammation, Dec 2013
Recent literature highlights that leucine-rich repeat kinase 2 (LRRK2), a kinase mutated in both autosomal-dominantly inherited and sporadic PD cases, modulates inflammation in response to different pathological stimuli.
Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies.
Review
New
Lewis et al., London, United Kingdom. In Faseb J, Sep 2013
We propose that the genetic forms of Parkinson's disease largely associated with α-synuclein-positive neuropathology (SNCA, LRRK2, and GBA) are brought together by involvement in the autophagy/lysosomal pathway and that this represents a unifying pathway to disease in these cases.
Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Review
New
Moore et al., Lausanne, Switzerland. In Small Gtpases, Jul 2013
Mutations in the leucine-rich repeat kinase 2 (LRRK2, PARK8, OMIM 607060) gene represent the most common known cause of hereditary Parkinson's disease (PD) with late-onset and dominant inheritance.
Lysosomal impairment in Parkinson's disease.
Review
New
Bezard et al., Bordeaux, France. In Mov Disord, Jun 2013
Furthermore, other PD-related genes, such as leucine-rich repeat kinase-2 (LRRK2), parkin, and phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1), have been mechanistically linked to alterations in ALPs.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
New
Impact
Sterneckert et al., Germany. In Cell Stem Cell, Apr 2013
The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Impact
Izpisua Belmonte et al., Beijing, China. In Nature, 2012
We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson's disease as well as impairment of adult neurogenesis in mice.
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
GeneRIF
Molnár et al., Budapest, Hungary. In Ideggyogy Sz, 2012
Data suggest that the mutation LRRK2 G2019S may be a rare cause of Parkinson disease in the Hungarian population.
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
GeneRIF
Kortholt et al., Groningen, Netherlands. In Proc Natl Acad Sci U S A, 2012
data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity
Number and brightness analysis of LRRK2 oligomerization in live cells.
GeneRIF
Jameson et al., Honolulu, United States. In Biophys J, 2012
results show, for the first time to our knowledge, that LRRK2 is predominantly monomeric throughout the cytosol of living cells, but attains predominately higher oligomeric states in the plasma membrane
GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.
GeneRIF
Chen et al., Shanghai, China. In Front Biosci (elite Ed), 2011
results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells
Evaluation of the role of LRRK2 gene in Parkinson's disease in an East Indian cohort.
GeneRIF
Ray et al., Calcutta, India. In Dis Markers, 2011
LRRK2 has minimal role as a candidate and susceptibility gene in Parkinson's disease pathogenesis among East Indians.
Pathological roles of α-synuclein in neurological disorders.
Review
Impact
Stefanis et al., Athens, Greece. In Lancet Neurol, 2011
α-Synuclein also seems to be linked to other genetic forms of Parkinson's disease, such as those linked to mutations in GBA or LRRK2, possibly through common effects on autophagy and lysosomal function.
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease.
Impact
GeneRIF
Lenardo et al., Bethesda, United States. In Nat Immunol, 2011
gene deficiency conferres enhanced susceptibility to experimental colitis
What genetics tells us about the causes and mechanisms of Parkinson's disease.
Review
Impact
Brice et al., Paris, France. In Physiol Rev, 2011
In contrast, α-synuclein accumulation in Lewy bodies defines a spectrum of disorders ranging from typical late-onset PD to PD dementia and including sporadic and autosomal dominant PD forms due to mutations in SCNA and LRRK2.
More papers using LRRK2 antibodies
Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase.
Supplier
Kahle Philipp J., In PLoS ONE, 1991
... The DR4A/3EDD anti-LRRK2-kinase domain antibody is described in reference [35] and goat polyclonal anti 14-3-3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
share on facebooktweetadd +1mail to friends